A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

Summary

This Phase 2 study was designed to evaluate the efficacy and safety of SNC-102 in subjects with drug-induced Tardive Dyskinesia (TD). To ensure an adequate evaluation of SNC-102, a randomized, double-blind, parallel-group, placebo-controlled trial was designed. Two dosing levels of SNC-102 are employed to evaluate the proposed dosing range. A target enrollment of 90 subjects with drug-induced TD will provide sufficient data to assess the efficacy and safety profiles of SNC-102 in the target population.

Timeline

Start

2014-02

Primary completion

2015-01

Completion

2015-12

Outcome

Outcome not reported

Stopped (Business): “Funding terminated; company closed”

Drugs

Indications